Stock Events

Stock Events

Mindset Pharma 

$0.54
8
-$0-0.37% Tuesday 21:55

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
48.9M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

30NovExpected
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q3 2022
-0.09
-0.06
-0.03
0
Expected EPS
N/A
Actual EPS
-0.0042

Financials

-425.28%Profit Margin
Unprofitable
2017
2018
2019
2020
2021
2022
3.09MRevenue
-13.12MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MSSTF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Compass Pathways
CMPS
Mkt Cap606.35M
Compass Pathways operates in the psychedelic medicine sector, focusing on psilocybin therapy for depression, similar to Mindset Pharma's focus on psychedelic treatments.
AtaiBeckley
ATAI
Mkt Cap1.56B
ATAI Life Sciences works on developing psychedelic and non-psychedelic compounds for mental health disorders, directly competing with Mindset Pharma's psychedelic-based therapies.
Cybin Inc
CYBN
Mkt Cap200.49M
Cybin Inc. focuses on developing psychedelic pharmaceuticals for mental health conditions, paralleling Mindset Pharma's objectives in the psychedelic space.
GH Research
GHRS
Mkt Cap888.26M
GH Research is developing a novel drug for treatment-resistant depression using 5-MeO-DMT, a psychedelic compound, which is a direct competitor to Mindset Pharma's psychedelic research.
Nuveen Municipal Income
NUMI
Mkt Cap0
Numinus Wellness focuses on psychedelic production and therapy, including regulatory approvals, directly competing with Mindset Pharma's approach to psychedelic drug development.
Revive Therapeutics
RVVTF
Mkt Cap4.68M
Revive Therapeutics explores the use of psychedelics in treatments for various ailments, including mental health disorders, competing with Mindset Pharma's research and development in psychedelics.
Noveris Health Sciences
MYCOF
Mkt Cap14.59M
Mydecine Innovations Group focuses on developing and commercializing psychedelic medicines, including therapies for mental health, directly competing with Mindset Pharma's product pipeline.

About

Mindset Pharma Inc. develops and sells psychedelic medicines to treat neurological and psychiatric disorders in Canada. It focuses on developing MSP-1014, a psychedelic drug candidate. The company is based in Toronto, Canada.
Show more...
CEO
Mr. James Andre-Charles Lanthier
Country
CA
ISIN
CA60268M1023
WKN
000A2QK93

Listings

0 Comments

Share your thoughts

FAQ

What is Mindset Pharma stock price today?▼
The current price of MSSTF is $0.54 USD — it has decreased by -0.37% in the past 24 hours. Watch Mindset Pharma stock price performance more closely on the chart.
What is Mindset Pharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Mindset Pharma stocks are traded under the ticker MSSTF.
What is Mindset Pharma market cap?▼
Today Mindset Pharma has the market capitalization of 48.9M
What were Mindset Pharma earnings last quarter?▼
MSSTF earnings for the last quarter are -0 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Mindset Pharma revenue for the last year?▼
Mindset Pharma revenue for the last year amounts to 3.09M USD.
What is Mindset Pharma net income for the last year?▼
MSSTF net income for the last year is -13.12M USD.
In which sector is Mindset Pharma located?▼
Mindset Pharma operates in the Healthcare sector.
When did Mindset Pharma complete a stock split?▼
Mindset Pharma has not had any recent stock splits.
Where is Mindset Pharma headquartered?▼
Mindset Pharma is headquartered in Toronto, CA.